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Abstract
prostate cancer (pca) is a heterogeneous disease with regard to molecu-
lar alterations and clinical course. the investigation of genetic alterations 
associated with pca pathogenesis is highly challenging. genome-wide 
analyses and epidemiological studies have identified only a handful of 
candidate genes possibly associated with hereditary or sporadic pca. 
cancer cells often rely for survival on common biochemical pathways 
such as enhanced anaerobic glycolysis and lipogenesis. the lipogenic 
enzyme fatty acid synthase seems to play a crucial part in pca by confer-
ring growth and survival advantages to cancer cells. We summarize the 
current understanding of the molecular events in pca, and highlight the 
importance of altered lipid metabolism in the development and progres-
sion of prostate malignancy.
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The clinical problem
Epidemiology
Among the male population of the USA, prostate cancer is the 
most prevalent non-cutaneous neoplasm (1 in 6 men will be 
diagnosed with PCa cancer during their lifetime) and a leading 
cause of cancer-related death, second only to lung and colon 
cancer.1 Its frequency varies widely, with the highest rates 
reported in Western countries, and the lowest rates in Asia.2 
Multiple factors contribute to the high incidence and prevalence 
of PCa. Risk factors include age, family history and race, but 
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(BMI) and adult weight gain increase the risk of dying from 
prostate cancer.3
Stage migration and risk stratification
The early 1990s saw a dramatic increase in the incidence of pros-
tate cancer with the introduction of the prostate-specific antigen 
(PSA) blood screening test. As screening became more wide-
spread in the USA, there was a significant stage migration toward 
detection of prostate cancer at earlier stages. For example, results 
at the time of diagnosis dropped from 16% in the 1980s to 4% in 
2003.4 In 2004, results from the Prostate Cancer Prevention trial 
showed that even men with PSA less than the traditional cut-off 
of 4.0 ng/ml had a substantial risk of harbouring prostate can-
cer (15.2% for all patients with PSA < 4.0; 26.9% for patients 
with PSA 3.1–4.0), which led many clinicians to use variations 
in PSA measurement as an indication to biopsy of men with PSA 
< 4.0, thereby further augmenting the continued stage migration 
effect.5
Among men with clinically localized prostate cancer, treat-
ment decisions of whether to pursue a local-only therapy (e.g. 
surgery, radiation, brachytherapy) versus a more aggressive 
combined method therapy (radiation plus hormones) is typically 
made based on the risk of recurrence. The commonest stratifica-
tion system was developed by D’Amico et al. and uses clinical 
T-stage, PSA, and Gleason score to divide patients into low, inter-
mediate, and high risk.6 Due to stage migration, the proportion 
of people with low-risk disease increased from 30% in 1990 to 
45% in 2000, and it is likely that low-risk disease represents most 
diagnoses of prostate cancer.7
For patients with low-risk disease, it is likely that a large pro-
portion do not need treatment. The risk stratification system is 
not good enough to discern, based on clinical and pathologi-
cal parameters, which low-risk patients have disease that will 
never progress from those who will die from their disease if left 
untreated (even though these represent the minority of low-risk 
patients). The net result is that many patients who do not need 
treatment may choose to be treated and suffer side effects unnec-
essarily, while others who need treatment may forgo therapy 
and miss a crucial opportunity to be cured. There is therefore a 
significant need for an improved risk-stratification system that 
incorporates novel biomarkers from relevant pathways to better 
determine the risk of recurrence and allow patients to make more 
informed decisions about treatment. Patients who recur and 
then develop metastases may be treated with androgen depriva-
tion therapy for a while, but nearly all will eventually develop 
androgen-independent disease if they do not die of other causes. 
Median survival in the androgen-independent state is only ~18 
months, and few treatment options are available which have 
shown benefit at this stage besides docetaxel, which extends 
life expectancy by only ~2–3 months over the prior standard 
of care.8 There is an equally urgent need to investigate relevant 
pathways in prostate cancer for new biomarkers and risk stratifi-
cation, and for the development of novel agents that can prolong 
survival.
This review discusses genetic markers and molecular path-
ways in prostate cancer with a particular emphasis on fatty acid 
synthase (FASN) and its possible role as a biomarker and thera-
peutic target. © 2008 elsevier ltd. all rights reserved.
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Analyses of polymorphic microsatellites have shown that multi-
ple foci of cancer arise independently within the same prostate.9 
An increasing number of studies prove that prostate cancer can 
be genetically classified into different subgroups, exemplifying 
the extensive phenotypic and molecular heterogeneity of this dis-
ease. Genetic profile analyses have detected only a few, poten-
tially significant mutations in hereditary and sporadic prostate 
cancer.
Hereditary PCa
Difficulties in identifying genes that are highly penetrant in PCa 
can be attributed to:
 •  the advanced age of patients at PCa onset (median age: 60 
years) makes the collection and molecular analyses of sam-
ples from more than two generations almost impossible
 •  the high frequency of PCa makes it difficult to distinguish spo-
radic cases from hereditary cases in families with high rates of 
disease
 •  hereditary PCas do not have specific clinical (except perhaps 
an earlier age of onset) or pathological characteristics that 
 differentiate them from sporadic cases.
Several studies have shown a familial predisposition for PCa. 
Over the last two decades, genome-wide analyses and genetic 
epidemiologic studies of PCa have led to the identification of 
high-risk alleles at several genetic loci.10 However among these, 
only a few candidate genes may be promising, in particular RNA-
seL and MSR.
RNAse L expresses an endoribonuclease related to the antiviral 
and pro-apoptotic interferon-induced activities and maps to the 
HPC1 locus at 1q24-25. MSR1 encodes for a macrophage-specific 
receptor that binds polyanionic ligands (including bacteria, oxi-
dized serum lipoproteins, apoptotic cells) and is located on 8p22-
23. Alterations in these two genes appear to be associated with 
progression and severity of PCa. Unlike breast cancer, for which 
familiar predisposition is strongly linked to polymorphisms in 
the genes BCRA 1 and BCRA 2, alterations in the RNAse L and/
or MSR1 genes do not account for most hereditary PCa cases. 
Freedman et al., using a whole-genome single nucleotide poly-
morphism analysis (SNP), identified a new locus at 8q24 that 
increases the risk for PCa in African-Americans and is associ-
ated with early onset of the malignancy.11 They also showed that 
the alleles previously identified in this locus12 are insufficient to 
explain the frequency of 8q24 amplification, pointing out that 
unmapped risk alleles in this region are yet to be identified. This 
line of investigation appears to hold the most promise to shed 
light on the pathogenesis of hereditary PCa.
Sporadic PCa
Sporadic PCa often shows heterogeneous patterns of oncogene 
activation, and is rarely associated with mutations in classic 
oncogenes or tumour suppressor genes. For these reasons the 
investigation of oncogene expression profile correlated to disease 
development and progression is highly challenging. Recently, 
genome-wide tools (e.g. comparative genome hybridization, 
spectral karyotyping, SNP analysis) have provided insight into 
common PCa chromosomal alterations13 As for hereditary PCa, diagnostic histopathology ■:■ 2
Please cite this article in press as: Elisa Benedettini, et al., The pathogenesis of prosta
doi:10.1016/j.mpdhp.2008.03.001only a handful of candidate genes have shown promise in having 
a causative role.14 These genes can be distinguished into those 
playing an active part in the early and those in the late phases of 
carcinogenesis. Genes having a putative role in tumour initiation 
encode for:
 •  the tumour suppressor proteins Pten, p27, Nkx3.1and Rb
 •  the transcription factor Myc
 •  glutathione S-transferase-π (GSTP1) which has a role on 
 damage-related stress prevention
 •  hepsin (cell-surface serine protease)
 •  Alpha-methylacyl-CoA racemase (AMACR), an enzyme 
 involved in β-oxidation of branched-chain fatty acids.
The genes aforesaid have been found to be overexpressed in 
most gene expression profiling studies.15 KLF6, a zinc finger tran-
scription factor, the polycomb protein EZH2 (enhancer of zeste 
homolog 2) and telomerase have also been implicated as well in 
the early phases of prostate carcinogenesis.
In contrast, genes involved in cancer progression and metas-
tases include the androgen receptor (AR) p53, Bcl2, ETV1 and 
ERG1. The role in tumour development and progression for 
most of the genes mentioned above has been supported by rel-
evant mouse models generated in the last two decades, which 
often mimic many of the characteristics of the human cancer.16 
Most models result in focal areas of prostatic intraepithelial neo-
plasia (PIN), but not in infiltrating tumours,17 suggesting that 
individual aberrant activation/deletion of these genes is not suf-
ficient to produce invasive PCa and may require other secondary 
events for cancer progression. Other models rapidly progress to 
local invasive adenocarcinoma followed by metastasis, as c-myc 
transgenic mice, prostate conditional Pten knockout, and the 
compound mice Pten +/−; p27 null, and p53- Rb- conditional 
knock-out mice.16
Along with mutations in individual genes, a chromosomal 
translocation has recently been identified in >50% of PCa. 
By using a bioinformatics approach able to discover candidate 
oncogenic chromosomal aberrations on the basis of outlier gene 
expression (COPA), strong and mutually exclusive outlier pro-
files for ERG and ETV1 (both members of ETS transcription factor 
family) were identified in PCa patients18 This imbalance resulted 
from the fusion of TMPRSS2 (21q22.2), coding for an androgen-
regulated transmembrane serine protease, with ERG (21q22.3) 
or ETV1 (7p21.2) (and rarely with other members of the ETS 
family) and represents the commonest rearrangement identi-
fied in human solid tumours. As a consequence, ERG and ETV1 
oncogenes are regulated by the androgen-responsive promoter 
of TMPRSS2, possibly providing a selective mechanism for early 
transformation. The occurrence of TMPRSS2:ERG or TMPRSS2:
ETV1 translocations appears to be mutually exclusive, suggest-
ing a specific mechanism required for tumour initiation or, more 
likely, maintenance. The TMPRSS2:ERG rearrangement, the com-
monest, is rather complex because both genes are located on the 
same chromosome and have the same transcriptional orienta-
tion. The translocation can generate 8 different types of mRNA, 
by alternative splicing and variant breakpoints.19 One of these 
mRNAs, known as TMPRSS2 ATG (with the translation initiation 
codon ATG of TMPRSS2 in frame with the exon 4 of ERG pro-
tein), seems to be associated with aggressive disease.19
Over the last decade, PCa has also been investigated for 
epigenetic changes—inheritable gene expression alterations © 2008 elsevier ltd. all rights reserved.
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of relevance. Studies on DNA methylation status have shown 
 hypermethylation of CpG islands in the promoter of several 
tumour suppressor genes—e.g. Rb, p16INK4A, MLH1, MSH2, 
GSTP1 and APC1—which are thereby transcriptionally silenced.20 
Most promising among many potential oncogenetic candidates is 
GSTP1, a member of a family of enzymes playing an important 
part in cell detoxification. Methylation of GSTP1 is detected in 
several cancer types, including breast and hepatocellular car-
cinomas, but only in PCa does it have a prevalence of >90% 
(reviewed in21). This alteration has also been detected with high 
frequency in proliferative inflammatory atrophy (PIA). PIA is pro-
posed to be a common proliferative response to environmental 
damage and, because it may be seen in proximity to high-grade 
prostatic intraepithelial neoplasia (HGPIN) and expresses molec-
ular signals of early neoplastic transformation (that is, GSTP1 
hypermethylation) it has been suggested that PIA is an early pre-
cursor of PCa (reviewed in 21).
Recently, GSTP1 methylation analysis has been detected in 
cell-free circulating DNA, which has turned out to be a promis-
ing seric biomarker of PCa detection and possibly biochemical 
recurrence.22
Metabolic alterations in tumour initiation and in 
androgen-independent disease
Pioneering efforts on the characterization of tumour metabolism 
have revealed that cancer cells rely on anaerobic pathways to 
convert glucose to ATP, even in abundant oxygen.23 This phe-
nomenon, known as the Warburg effect, occurs despite the fact 
that the anaerobic pathway is less efficient for energy supply 
than aerobic respiration.
Warburg claimed that the first phase of cancer genesis is 
irreversible injury to the respiratory chain. Due to the result-
ing defective aerobic energy prodution, injured cells switch to 
fermentation (glycolysis with lactate as the final product) to 
survive.23 If on the one hand glycolysis is less efficient than 
aerobic respiration, on the other hand it produces ATP at a rate 
100-times faster than mitochondrial oxidation. Tumour cells 
therefore efficiently extract glucose from the host and process 
it by adaptive metabolic activities. The high intake of glucose 
provides, by pyruvate synthesis, energy and a readily available 
source of acetyl CoA for mitochondrial synthesis of citrate, nec-
essary for fatty acid/cholesterol synthesis (Figure 1).24 Under 
normal conditions, most fatty acids are derived from intake in 
food, and their endogenous synthesis is usually minimal while, 
in tumour cells, almost all fatty acids are produced via de novo 
synthesis, despite high levels of ambient fatty acids.25 Thus it is 
speculated that the increased metabolism of glucose contributes 
to the tumorigenic process by promoting de novo synthesis of 
fatty acids,26 even if the mechanism by which fatty acids might 
promote prostate cancer growth and survival is poorly under-
stood. Consistent with this hypothesis, numerous studies show 
that most lipogenic enzymes, such as fatty acid synthase (FASN) 
and acetyl-CoA carboxylase, are overexpressed in a wide vari-
ety of tumour types. The overexpression of FASN in the prostate 
occurs during the earliest stages of neoplastic transformation 
(PIN lesions) and in nearly all invasive prostate carcinomas.21,25 
Altered metabolism is not a cause of malignancies, although diagnostic histopathology ■:■ 
Please cite this article in press as: Elisa Benedettini, et al., The pathogenesis of prostat
doi:10.1016/j.mpdhp.2008.03.001tumour cells may depend on altered metabolic pathways (see 
below).
Next, we review the evidence supporting a crucial role of 
fatty acid-related metabolism in the pathogenesis and progres-
sion of prostate malignancy, pointing out that the understanding 
of the alterations in intermediary metabolism of prostate cells 
may offer new opportunities in the prevention, diagnosis and 
treatment of PCa.
FASN as a metabolic oncogene in PCa
FASN, a 270 kD cytosolic complex enzyme that functions as a 
homodimer, catalyzes the synthesis of palmitate by the conden-
sation of malonyl-CoA and acetyl-CoA. FASN plays an important 
part in energy homeostasis by converting excess carbon intake 
into fatty acids for storage. For the reason mentioned above, 
FASN is expressed at low-to-undetectable levels in normal adult 
human tissues, except in the liver, adipose tissue, and breast of 
lactating women. FASN is overexpressed in many human can-
cers, including PCa.27 We have previously shown that FASN 
expression progressively increases throughout the natural history 
of a substantial proportion (two-thirds) of PCas, beginning with 
PIN, and reaching the highest values in androgen-independent 
PCas metastatic to bone. FASN-overexpressing PCas have a dis-
tinctive gene expression signature.28
Human PCas have genomic amplification of FASN (reviewed 
in26), suggesting that FASN confers a selective growth advantage 
to tumour cells. The biochemical and metabolic basis for this 
overexpression and its consequences are not well understood, 
but it is known that prostate tumours expressing high FASN lev-
els are associated with poor prognosis (rev in29).
Treatment of human PCa cell lines with cerulenin, a natu-
ral irreversible inhibitor of FASN, reduces cell proliferation and, 
more significantly, induces cell death,26,30 while systemic treat-
ment of nude mice bearing PCa xenografts with the more stable 
fatty acid synthase inhibitor C75 (α-methylene-γ-butyrolactone) 
significantly reduces the size of PCa masses that overexpress 
FASN.30 A recent study has shown that FASN expression and 
activity is higher in TRAMP mouse models compared to non-
transgenic littermates, and increases with age, tumour progres-
sion, and in metastatic lesions. In these models, FASN activity 
inhibited by cerulenin and C-75 results in apoptosis.31
Polyphenol epigallocatecin gallate (EGCG), in part responsible 
for the cancer-preventive effects of green tea, is also a potent 
inhibitor of fatty acid synthase.26
The negligible activity of FASN in normal tissues and its seem-
ingly essential role in tumours, begs the question ‘why FASN 
activity is essential for tumour cell survival?’ Several hypotheses 
can be entertained.
 (1) FASN has been shown to maintain membrane biogenesis 
for the endoplasmatic reticulum (ER), which is specialized in 
the synthesis and transport of secretory and membrane proteins, 
as well as of phospholipids. A recent study showed that FASN 
inhibitors induce ER stress in tumour cells.32 ER stress is a co-
ordinated cellular response to alterations of ER homeostasis that 
results in the activation of an adaptive survival response. The 
same study showed that FASN inhibitors cooperate with the ER 
stress-inducer thapsigargin to cause cell death. It has thus been 
proposed that FASN overexpression in tumour cells may be nec-
essary to preserve ER function.© 2008 elsevier ltd. all rights reserved.
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Figure 1 lipogenesis from glucose metabolism and lipid rafts genesis. the pathway involving the conversion of glucose to fatty acids (Fas) begins 
with citrate metabolism. in healthy cells, citrate is fully oxidized into the Krebs cycle to generate atp. in tumour cells, citrate is preferentially 
transported to the cytoplasm, where it is converted into acetyl-coa, which constitutes the building block of Fas. complex Fas, in turn, tend to 
partition into detergent-resistant membrane microdomains called lipid rafts, which have a role either in cell membranes genesis and in signalling 
molecules regulation. Key molecule in this metabolic switch–essential for tumour cells survival-is Fasn, the enzyme that catalyzes the first step of 
de novo synthesis of Fas. (2) Detergent-resistant membrane microdomains may be altered 
by increased lipid synthesis, thus affecting signal transduction. 
Most newly synthesized lipids are phospholipids enriched in sat-
urated and monounsaturated fatty acyl chains. These phospholi-
pids, together with cholesterol, tend to partition into detergent-
resistant membrane microdomains called lipid rafts (Figure 1)33 
Raft microdomains are also rich in proteins and serve as mem-
brane platforms for signal transduction in various cellular path-
ways, including the protein kinase C (PKC), mitogen-activated 
protein kinase (MAPK), and PI3K pathways. Lipid rafts mobilize 
and, thus, modulate the activity of the membranous second mes-
sangers of these pathways.34 The first evidence linking lipid rafts 
to PCa comes from the identification of the raft-associated protein 
caveolin1 (Cav-1) as a marker for aggressive PCa.35 In a recent 
study aimed at investigating Cav-1 in the onset and progression 
of PCa, Cav-1 null mice were interbred with TRAMP mice. Inac-
tivation of Cav-1 resulted in significant reductions in prostate tu-
mour size and occurrence of metastases.36 This effect appears to diagnostic histopathology ■:■ 
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Cav-1.37 Signal transduction through rafts in cancer cells may be 
also be caveolin-independent. Zhuang et al. demonstrated that, 
in caveolin-negative human PCa cells LNCaP, the EGFR-mediated 
activation of the PI3K/Akt signaling pathway is downregulated 
after treatment with the raft-disrupting agent filipin, and is totally 
recovered by repletion of the membrane with cholesterol. Treat-
ment with filipin alone resulted in cell apoptosis to a similar ex-
tent as the PI3K inhibitor, suggesting that the raft microdomains 
are prominent mediators of survival in PCa cells.38 Given the 
abundance of complex fatty acids in liquid-ordered lipid micro-
domains, FASN-driven increase in the proportion of membrane 
phospholipids may result in a modified organization of signalling 
proteins on the membrane, and thus in a deregulation of several 
processes (e.g. cell growth and survival).
 (3) PCa cells overexpressing FASN may rely on palmitate 
 metabolism to maintain their malignant phenotype. Many of the 
effects of FASN inhibition such as apoptosis, reactive oxygen © 2008 elsevier ltd. all rights reserved.
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been shown to be at least partially rescued by palmitate.39 Palmi-
tate, the principal product of FASN activity, is a signal for cel-
lular membrane localization and activation for many proteins. 
 Palmitoylation of oncogenic proteins like Ras and Wnt is an 
essential posttranslational modification critical for cancer pro-
gression.40 In prostate cells overexpressing FASN, global pro-
tein palmitoylation profiles reveal unique patterns compared 
to isogenic cells without FASN overexpression (Migita, Loda 
et al., unpublished), suggesting an important mechanism through 
which high levels of FASN, or possibly even exogenous fatty ac-
ids (such as those derived from the diet) can influence signalling 
in PCa cells.
 (4) Tumour cells consistently rely on anaerobic pathways: this 
limits their respiratory chain and, in turn, their oxidizing power. 
Cancer cells may therefore favour synthesis and chain elongation 
of fatty acids because they supply oxidizing power for key oxida-
tive steps, to improve the cellular redox balance despite hypoxic 
conditions.41This would accomplish a reduction in lactic acidosis 
and the synthesis of fatty acids to be utilized as structural lipids 
or as an energy source.
It is unclear which of the mechanisms mentioned above, by 
no means mutually exclusive, is principally responsible for the 
oncogenic properties of FASN.
FASN regulation: the sterol regulatory element binding pro-
teins (SREBPs) are key players in the transcriptional regulation 
of lipogenic enzymes. FASN transcription is modulated by the 
androgen-dependent SREBP1c in the androgen-dependent and 
ligand-independent (castration-resistant) state. The putative role 
of FASN in the progression of PCa toward androgen indepen-
dence is unknown. In the CWR22 model of PCa, FASN protein 
expression, tumour size and proliferation rate decrease after 
castration and return to normal with androgen replenishment.42 
However PCa in castrated mice, which relapsed after a long 
latency, displayed high levels of FASN protein, as well as tumour 
growth arrest by FASN inhibitors has been also achieved in some 
androgen-independent prostate cancer xenografts.39 These data 
suggest an androgen-independent regulation of FASN that is con-
firmed also in gene expression profile analysis of human pros-
tate cancers. Thus, FASN represents an attractive drug target in 
androgen-dependent and -independent disease.
A substantial number of PCa patients exhibit discordance 
between FASN mRNA and protein levels, suggesting post-
 transcriptional regulatory mechanisms.43 FASN protein levels 
are modulated via de-ubiquitination by the isopeptidase USP2a. 
USP2a is a pre-proteosomal, androgen-regulated de-ubiquitinat-
ing enzyme overexpressed in ~40% of PCa44 that plays a key part 
in PCa cell survival through stabilization of FASN protein.45 RNA 
interference of USP2a results in apoptosis of PCa cells, which is 
rescued by FASN overexpression, suggesting that FASN down-
regulation can also be achieved by targeting USP2a in PCa.
FASN and the metabolic syndrome (MS): MS is a pathologi-
cal condition characterized primarily by insulin resistance, and 
is associated with a high risk for cardiovascular disease and 
death. The overabundance of circulating fatty acids is the major 
contributor to the development of insulin resistance in diabetic 
patients.46 In large epidemiologic studies, obesity and the MS diagnostic histopathology ■:■ 
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men diagnosed with PCa, weight gain before and obesity at the 
time of cancer diagnosis are associated with an increased prob-
ability of PSA failure after prostatectomy.
Lack of AMPK (5’AMP-activated protein kinase) activity is 
associated with the MS.46 AMPK acts as an energy sensor or ‘fuel 
gauge’ with the ultimate aim of enhancing ATP generation in 
low fuel (high AMP/ATP) conditions and plays a crucial part in 
systemic energy balance by integrating nutritional and hormonal 
signals in peripheral tissues and also in the hypothalamus.26 
AMPK modulates FASN expression (by regulating the transcrip-
tional factor SREBP1c) and FASN activity (by phosphorylating 
and inhibiting acetyl-CoA carboxylase (ACC), which catalyzes 
the formation of malonyl CoA, the rate-limiting step in fatty acid 
synthesis, Figure 1).26 AMPK stimulation is capable of inhibiting 
FASN activity in vitro despite constitutive FASN expression in 
PCa cells.
Therefore, one could speculate that prolonged inactivation 
of AMPK may contribute to abnormal cellular metabolism and 
tumour cell transformation/survival through an increase in the 
availability of circulating fatty acids or the deregulated activity of 
FASN itself, thus linking predisposing dietary factors and intrin-
sic alterations of metabolic enzymes, such as FASN. Further evi-
dence is necessary to substantiate the hypothesis that chronic 
inactivation of AMPK results in unchecked activity of FASN.
FASN: structure–function relationship: The FDA-approved 
drug orlistat can induce apoptosis in FAS-overexpressing prostate 
tumours by inhibiting the thioesterase domain of FAS.39The struc-
ture of the thioesterase domain of FAS has been resolved.48 The 
structure of FAS26, USP249 and AMPK50 have also been defined. 
This will allow for the design of more specific drugs that will affect 
metabolic pathways crucial to the survival of PCa cells.
Conclusions
In this review, the authors suggested that interfering with lipid 
metabolism has detrimental effects on prostate tumour cell sur-
vival. Studies are under way to determine the precise mecha-
nisms responsible for tumour initiation and maintenance by 
altered metabolic pathways.
From a broader perspective, the authors would like to under-
score the necessity of more thorough investigations of the 
metabolic alterations in cancer, and speculate that combining 
metabolic profiling with genome-wide analyses will drive new 
understanding in PCa biology and subsequently treatment. ◆
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Practice points
 •  novel molecular biomarkers have the potential to improve 
risk stratification among patients with prostate cancer (pca) 
and allow for better decision-making about treatment.
 •  candidate high-risk genes that are potentially associated 
with hereditary pca are rnase l and Msr; many sporadic 
pcas, characterized by heterogeneous patterns of oncogene 
activation, show the commonest chromosomal rearrangement 
yet identified in human solid tumours, resulting in the fusion 
of tMprss2 (2q22.2) with erg (2q22.) or etV (7p2.2).
 •  upregulation of fatty acid synthase (Fasn), the key metabolic 
enzyme that is responsible for the terminal catalytic step in 
de novo synthesis of fatty acids (Fas), represents a common 
characteristic in human malignancies.diagnostic histopathology ■:■ 7
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 •  Fasn seems to play a crucial role in pca by conferring 
growth and survival advantages to cancer cells, maintaining 
membrane biogenesis and membranous signalling proteins 
regulation, and providing protein palmitoylation, which is a 
post-translational modification critical in cancer progression.
 •  the metabolic syndrome (Ms), which is a pathological 
condition characterized by primarily insulin resistance and 
associated with the overabundance of circulating fatty 
acids, has been related to risk of advanced pca. prolonged 
inactivation of aMpK in patients with pca may contribute to 
abnormal cellular metabolism and tumour cell transformation/
survival by promoting the unchecked activity of Fasn.
 •  tumour exacerbated lipogenesis might represent a potential 
marker in tumour diagnosis (because it emerges early in 
carcinogenesis) and a target in treatment of advanced 
carcinomas.© 2008 elsevier ltd. all rights reserved.
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